Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors

Journal of Virology

Volumn 82, Issue 21, 2008, Pages 10366-10374

  Goethals, Olivia ^a   Clayton, Reginald ^a   Van Ginderen, Marcia ^a   Vereycken, Inge ^a   Wagemans, Elisabeth ^a   Geluykens, Peggy ^a   Dockx, Koen ^a   Strijbos, Rudy ^a   Smits, Veerle ^a   Vos, Ann ^a   Meersseman, Geert ^a   Jochmans, Dirk ^a   Vermeire, Kurt ^b   Schols, Dominique ^b   Hallenberger, Sabine ^a   Hertogs, Kurt ^a  

^a TIBOTEC BVBA   (Belgium)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 4 OXO 4,6,7,8,9,10 HEXAHYDROPYRIMID[1,2 A]AZEPINE 2 CARBOXYLAMIDE; 4 [1 (4 FLUOROBENZYL) 2 PYRROLYL] 2,4 DIOXOBUTYRIC ACID; 9H PYRIDO[3,4 B]INDOLE 3 CARBOXAMIDE; ELVITEGRAVIR; INTEGRASE; INTEGRASE INHIBITOR; N (4 FLUOROBENZYL) 8 HYDROXY 5 (TETRAHYDRO 2H 1,2 THIAZIN 2 YL) 1,6 NAPHTHYRIDINE 7 CARBOXAMIDE S,S DIOXIDE; RALTEGRAVIR; UNCLASSIFIED DRUG; ZIDOVUDINE; P31 INTEGRASE PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; QUINOLONE DERIVATIVE;

ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG PROTEIN BINDING; DRUG SENSITIVITY; ENZYME ACTIVE SITE; ENZYME STRUCTURE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; VIRUS MUTATION; VIRUS REPLICATION; VIRUS STRAIN; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; GENETICS; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

CATALYTIC DOMAIN; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, VIRAL; HIV INTEGRASE; HIV-1; HUMANS; INTEGRASE INHIBITORS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MUTATION, MISSENSE; QUINOLONES;

EID: 55249105017     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00470-08     Document Type: Article

References (36)

1. Anker, M., and R. B. Corales. 2008. Raltegravir (MK-0518): a novel integrase inhibitor for the treatment of HIV infection. Expert Opin. Investig. Drugs. 17:97-103.
2. Asante-Appiah, E., and A. M. Skalka. 1997. Molecular mechanisms in retrovirus DNA integration. Antiviral Res. 36:139-156.
3. Belyk, K. M., H. G. Morisson, P. Jones, and V. Summa. June 2006. Potassium salt of an HIV integrase inhibitor. International patent WO2006060712.
4. Billich, A. 2003. S-1360 Shionogi-GlaxoSmithKline. Curr. Opin. Investig. Drugs 4:206-209.
5. Cahn, P., and O. Sued. 2007. Raltegravir: a new antiretroviral class for salvage therapy. Lancet 369:1235-1236.
6. Clavel, F., and A. J. Hance. 2004. HIV drug resistance. N. Engl. J. Med. 350:1023-1035.
7. Cox, A. G., and V. Nair. 2006. Novel HIV integrase inhibitors with anti-HIV activity: insights into integrase inhibition from docking studies. Antivir. Chem. Chemother. 17:343-353.
8. Dayam, R., R. Gundla, L. Q. Al-Mawsawi, and N. Neamati. 2008. HIV-1 integrase inhibitors: 2005-2006 update. Med. Res. Rev. 28:118-154.
9. DeJesus, E., D. Berger, M. Markowitz, C. Cohen, T. Hawkins, P. Ruane, R. Elion, C. Farthing, L. Zhong, A. K. Cheng, D. McColl, and B. P. Kearney. 2006. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J. Acquir. Immune Defic. Syndr. 43:1-5.
10. Deng, J., R. Dayam, L. Q. Al-Mawsawi, and N. Neamati. 2007. Design of second generation HIV-1 integrase inhibitors. Curr. Pharm. Des. 13:129-141.
11. Dicker, I. B., H. K. Samanta, Z. Li, Y. Hong, Y. Tian, J. Banville, R. R. Remillard, M. A. Walker, D. R. Langley, and M. Krystal. 2007. Changes to the HIV long terminal repeat and to HIV integrase differentially impact HIV integrase assembly, activity, and the binding of strand transfer inhibitors. J. Biol. Chem. 282:31186-31196.
12. Engelman, A., K. Mizuuchi, and R. Craigie. 1991. HIV-1 DNA integration: mechanism of viral DNA cleavage and DNA strand transfer. Cell 67:1211-1221.
13. Esposito, D., and R. Craigie. 1999. HIV integrase structure and function. Adv. Virus Res. 52:319-333.
14. Fikkert, V., A. Hombrouck, B. Van Remoortel, M. De Maeyer, C. Pannecouque, E. De Clercq, Z. Debyser, and M. Witvrouw. 2004. Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360. AIDS 18:2019-2028.
15. Gerton, J. L., S. Ohgi, M. Olsen, J. DeRisi, and P. O. Brown. 1998. Effects of mutations in residues near the active site of human immunodeficiency virus type 1 integrase on specific enzyme-substrate interactions. J. Virol. 72:5046-5055.
16. Goldgur, Y., R. Craigie, G. H. Cohen, T. Fujiwara, T. Yoshinaga, T. Fujishita, H. Sugimoto, T. Endo, H. Murai, and D. R. Davies. 1999. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc. Natl. Acad. Sci. USA 96:13040-13043.
17. Greenwald, J., V. Le, S. L. Butler, F. D. Bushman, and S. Choe. 1999. The mobility of an HIV-1 integrase active site loop is correlated with catalytic activity. Biochemistry 38:8892-8898.
18. Grinsztejn, B., B. Y. Nguyen, C. Katlama, J. M. Gatell, A. Lazzarin, D. Vittecoq, C. J. Gonzalez, J. Chen, C. M. Harvey, and R. D. Isaacs. 2007. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 369:1261-1269.
19. Hazuda, D. J., N. J. Anthony, R. P. Gomez, S. M. Jolly, J. S. Wai, L. Zhuang, T. E. Fisher, M. Embrey, J. P. Guare, Jr., M. S. Egbertson, J. P. Vacca, J. R. Huff, P. J. Felock, M. V. Witmer, K. A. Stillmock, R. Danovich, J. Grobler, M. D. Miller, A. S. Espeseth, L. Jin, I. W. Chen, J. H. Lin, K. Kassahun, J. D. Ellis, B. K. Wong, W. Xu, P. G. Pearson, W. A. Schleif, R. Cortese, E. Emini, V. Summa, M. K. Holloway, and S. D. Young. 2004. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc. Natl. Acad. Sci. USA 101:11233-11238.
20. Hazuda, D. J., P. Felock, M. Witmer, A. Wolfe, K. Stillmock, J. A. Grobler, A. Espeseth, L. Gabryelski, W. Schleif, C. Blau, and M. D. Miller. 2000. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287:646-650.
21. Horwitz, J., J. Chua, and M. Noel. 1964. Nucleosides. V. The monomesylates of 1-(2′-deoxy-β-D-lyxofuranosyl)thymidine. J. Org. Chem. 29:2076-2078.
22. Johnson, A. A., W. Santos, G. C. Pais, C. Marchand, R. Amin, T. R. Burke, Jr., G. Verdine, and Y. Pommier. 2006. Integration requires a specific interaction of the donor DNA terminal 5′-cytosine with glutamine 148 of the HIV-1 integrase flexible loop. J. Biol. Chem. 281:461-467.
23. Kuki, A., X. Li, M. B. Plewe, H. Wang, and J. Zhang. July 2005. HIVintegrase inhibitors, pharmaceutical compositions, and methods for their use. U.S. patent 7,138,408.
24. LaFemina, R. L., C. L. Schneider, H. L. Robbins, P. L. Callahan, K. LeGrow, E. Roth, W. A. Schleif, and E. A. Emini. 1992. Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells. J. Virol. 66:7414-7419.
25. Lataillade, M., J. Chiarella, and M. J. Kozal. 2007. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir. Ther. 12:563-570.
26. Malet, I., O. Delelis, M. A. Valantin, B. Montes, C. Soulie, M. Wirden, L. Tchertanov, G. Peytavin, J. Reynes, J. F. Mouscadet, C. Katlama, V. Calvez, and A. G. Marcelin. 2008. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob. Agents Chemother. 52:1351-1358.
27. Pommier, Y., A. A. Johnson, and C. Marchand. 2005. Integrase inhibitors to treat HIV/AIDS. Nat. Rev. Drug Discov. 4:236-248.
28. Reinke, R., D. J. Lee, and W. E. Robinson, Jr. 2002. Inhibition of human immunodeficiency virus type 1 isolates by the integrase inhibitor L-731,988, a diketo acid. Antimicrob. Agents Chemother. 46:3301-3303.
29. Sakai, H., M. Kawamura, J. Sakuragi, S. Sakuragi, R. Shibata, A. Ishimoto, N. Ono, S. Ueda, and A. Adachi. 1993. Integration is essential for efficient gene expression of human immunodeficiency virus type 1. J. Virol. 67:1169-1174.
30. Sato, M., T. Motomura, H. Aramaki, T. Matsuda, M. Yamashita, Y. Ito, H. Kawakami, Y. Matsuzaki, W. Watanabe, K. Yamataka, S. Ikeda, E. Kodama, M. Matsuoka, and H. Shinkai. 2006. Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J. Med. Chem. 49:1506-1508.
31. Savarino, A. 2007. In-silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate. Retrovirology 4:21.
32. Scarth, B., and M. Götte. 2007. The A62V mutation in HIV-1 reverse transcriptase increases the inhibitory effects of the PPi analogue Foscarnet, abstr. 586. Abstr. 14th Conf. Retrovir. Opportunistic Infect., Los Angeles, CA, 25 to 28 February 2007.
33. Shimura, K., E. Kodama, Y. Sakagami, Y. Matsuzaki, W. Watanabe, K. Yamataka, Y. Watanabe, Y. Ohata, S. Doi, M. Sato, M. Kano, S. Ikeda, and M. Matsuoka. 2008. Broad anti-retroviral activity and resistance profile of a novel human immunodeficiency virus integrase inhibitor, elvitegravir (JTK-303/GS-9137). J. Virol. 82:764-774.
34. van Gent, D. C., K. Mizuuchi, and M. Gellert. 1996. Similarities between initiation of V(D)J. recombination and retroviral integration. Science 271: 1592-1594.
35. Vingerhoets, J., H. Azijn, E. Fransen, I. De Baere, L. Smeulders, D. Jochmans, K. Andries, R. Pauwels, and M. P. de Bethune. 2005. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J. Virol. 79:12773-12782.
36. Witvrouw, M., B. Van Maele, J. Vercammen, A. Hantson, Y. Engelborghs, E. De Clercq, C. Pannecouque, and Z. Debyser. 2004. Novel inhibitors of HIV-1 integration. Curr. Drug Metab. 5:291-304.